ASH 2023|"The Voice of Lu DaoPei" sings on the international stage
The American Society of Hematology (ASH) is the top academic meeting in the field of haematology worldwide. The fact that Lu DaoPei Hospital has been selected as a finalist for the ASH for consecutive years fully demonstrates its academic achievements in the field and also reflects the recognition of Lu DaoPei's medical team by global authorities in the field of haematology. In the future, we will continue to research and create safer and more effective diagnostic and therapeutic solutions to achieve better clinical cures and long-term survival for the majority of haematological patients!
The 65th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA from December 9 to 12, 2023. As the largest and most influential annual meeting in the field of international hematology, the ASH Congress attracts tens of thousands of hematology experts and clinicians from all over the world every year. The academic reports presented represent the most important and cutting-edge research results in the field of hematology.
Dean Lu Peihua, academic leader of Lu DaoPei Hospital, led the team to the meeting site to exchange, learn and share with hematology experts and scholars from all over the world through 1 oral report and 9 wall newspaper displays.
At 2:00 p.m. local time on December 9, the clinical research results of "Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid leukemia: Phase I Clinical Trial" orally reported by Dean Lu Peihua received a lot of attention.
Dean Lu Peihua mentioned in the report that the research results show the significant efficacy and safety of CD7 CAR-T (NS7CAR-T). Although limited by the sample size, more data will undoubtedly be obtained through more patient groups and longer follow-up time for further verification, but these also give the clinic great hope and confidence.
It is worth mentioning that, as the first offline group participation since the epidemic, there are many young doctors in the team attending the meeting in the United States. Lu Daopei Medical Group has invested a lot of energy in the training of young doctors, and they have also lived up to expectations. Of the 10 research results selected by the team at this annual meeting, 5 were written by young and middle-aged doctors of the team.
In order to continuously improve the level of diagnosis and treatment of hematological tumors and bring new hope to more patients, Lu DaoPei's medical team has shone brilliantly on many academic stages at home and abroad. Since 2018, the team has reported research results more than 150 times at international hematological conferences and published more than 300 academic papers. Every year, Lu DaoPei's team can be seen at top international hematology events such as ASH, EHA, EBMT, JSH, etc.
By the end of December 2022, Lu DaoPei Medical Group had completed a total of 7852 hematopoietic stem cell transplants, of which 5597 were haploidentical transplants, accounting for 71.9% of the total number of transplants. These remarkable achievements in the industry have benefited from the continuous exploration of the team, which has established a strong influence and good reputation in the industry and patient groups.